Kane Biotech Inc
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface pol… Read more
Market Cap & Net Worth: Kane Biotech Inc (KNBIF)
Kane Biotech Inc (OTCQB:KNBIF) has a market capitalization of $10.58 Million ($10.58 Million) as of March 18, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #30698 globally and #10108 in its home market, demonstrating a 0.57% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kane Biotech Inc's stock price $0.07 by its total outstanding shares 150262000 (150.26 Million).
Kane Biotech Inc Market Cap History: 2015 to 2025
Kane Biotech Inc's market capitalization history from 2015 to 2025. Data shows change from $24.79 Million to $10.58 Million (-9.28% CAGR).
Kane Biotech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kane Biotech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.35x
Kane Biotech Inc's market cap is 3.35 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $24.79 Million | $104.62K | -$1.71 Million | 236.97x | N/A |
| 2016 | $6.91 Million | $244.76K | -$2.55 Million | 28.24x | N/A |
| 2017 | $13.36 Million | $1.04 Million | -$2.79 Million | 12.90x | N/A |
| 2018 | $9.51 Million | $506.27K | -$3.26 Million | 18.79x | N/A |
| 2019 | $15.78 Million | $1.69 Million | -$960.18K | 9.32x | N/A |
| 2020 | $16.87 Million | $1.34 Million | -$3.72 Million | 12.58x | N/A |
| 2021 | $18.59 Million | $1.61 Million | -$4.60 Million | 11.56x | N/A |
| 2022 | $9.02 Million | $2.67 Million | -$3.89 Million | 3.38x | N/A |
| 2023 | $9.20 Million | $2.74 Million | -$4.32 Million | 3.35x | N/A |
Competitor Companies of KNBIF by Market Capitalization
Companies near Kane Biotech Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Kane Biotech Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Kane Biotech Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Kane Biotech Inc's market cap moved from $24.79 Million to $ 10.58 Million, with a yearly change of -9.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $10.58 Million | -18.89% |
| 2024 | $13.04 Million | +41.83% |
| 2023 | $9.20 Million | +2.00% |
| 2022 | $9.02 Million | -51.50% |
| 2021 | $18.59 Million | +10.15% |
| 2020 | $16.87 Million | +6.95% |
| 2019 | $15.78 Million | +65.88% |
| 2018 | $9.51 Million | -28.80% |
| 2017 | $13.36 Million | +93.26% |
| 2016 | $6.91 Million | -72.12% |
| 2015 | $24.79 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Kane Biotech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.58 Million USD |
| MoneyControl | $10.58 Million USD |
| MarketWatch | $10.58 Million USD |
| marketcap.company | $10.58 Million USD |
| Reuters | $10.58 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.